Roy S. Herbst, MD, PhD, Yale Cancer Center

Immunotherapy for NSCLC: Clinical Pearls

Mark A. Socinski, MD, AdventHealth Cancer Institute;Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute;Roy S. Herbst, MD, PhD, Yale Cancer Center;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Sandip P. Patel, MD, University of California San Diego;Neal Edward Ready, MD, PhD, Duke Medical Center

August 25th 2021

Final takeaways from ASCO 2021 and the use of immunotherapy to treat various types of patients with non–small cell lung cancer.

CRT and I-O for Unresectable Stage III NSCLC

Mark A. Socinski, MD, AdventHealth Cancer Institute;Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute;Roy S. Herbst, MD, PhD, Yale Cancer Center;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Sandip P. Patel, MD, University of California San Diego;Neal Edward Ready, MD, PhD, Duke Medical Center

August 4th 2021

Martin Dietrich, MD, PhD, describes his interpretations of the KEYNOTE-799 study of pembrolizumab plus chemoradiation therapy for unresectable stage III non–small cell lung cancer.

Appropriateness for Durvalumab in Unresectable Stage III NSCLC

Mark A. Socinski, MD, AdventHealth Cancer Institute;Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute;Roy S. Herbst, MD, PhD, Yale Cancer Center;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Sandip P. Patel, MD, University of California San Diego;Neal Edward Ready, MD, PhD, Duke Medical Center

August 4th 2021

Variables that influence patient selection for durvalumab consolidation after CRT as part of treatment for unresectable stage III non–small cell lung cancer.

Risks of Pneumonitis in Unresectable Stage III NSCLC

Mark A. Socinski, MD, AdventHealth Cancer Institute;Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute;Roy S. Herbst, MD, PhD, Yale Cancer Center;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Sandip P. Patel, MD, University of California San Diego;Neal Edward Ready, MD, PhD, Duke Medical Center

July 28th 2021

How to differentiate whether a patient with unresectable stage III non–small cell lung cancer develops pneumonitis from chemoradiation or durvalumab, and insight regarding techniques to help manage treatment toxicities.

Durvalumab for Unresectable Stage III NSCLC

Mark A. Socinski, MD, AdventHealth Cancer Institute;Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute;Roy S. Herbst, MD, PhD, Yale Cancer Center;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Sandip P. Patel, MD, University of California San Diego;Neal Edward Ready, MD, PhD, Duke Medical Center

July 28th 2021

Chaitali Nangia, MD, of the Patty and George Hoag Cancer Center, reacts to the significance of the 5-year overall survival data for the PACIFIC trial evaluating the use of durvalumab after chemoradiation as treatment for inoperable stage III non–small cell lung cancer.

Second-Line Therapy for Stage IV NSCLC

Mark A. Socinski, MD, AdventHealth Cancer Institute;Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute;Roy S. Herbst, MD, PhD, Yale Cancer Center;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Sandip P. Patel, MD, University of California San Diego;Neal Edward Ready, MD, PhD, Duke Medical Center

July 21st 2021

Second-line treatment recommendations for patients with stage IV non–small cell lung cancer who experience disease progression after immunotherapy.

Frontline Treatment of Stage IV NSCLC: What’s Next?

Mark A. Socinski, MD, AdventHealth Cancer Institute;Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute;Roy S. Herbst, MD, PhD, Yale Cancer Center;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Sandip P. Patel, MD, University of California San Diego;Neal Edward Ready, MD, PhD, Duke Medical Center

July 21st 2021

Future projections regarding the role of novel I-O therapies as frontline treatment for patients with metastatic non–small cell lung cancer.

Immune-Related Adverse Events in NSCLC

Mark A. Socinski, MD, AdventHealth Cancer Institute;Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute;Roy S. Herbst, MD, PhD, Yale Cancer Center;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Sandip P. Patel, MD, University of California San Diego;Neal Edward Ready, MD, PhD, Duke Medical Center

July 14th 2021

Recommendations for managing immune-related adverse events associated with checkpoint inhibitors used to treat stage IV non–small cell lung cancer.

Frontline Treatment of Stage IV NSCLC: Biomarkers

Mark A. Socinski, MD, AdventHealth Cancer Institute;Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute;Roy S. Herbst, MD, PhD, Yale Cancer Center;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Sandip P. Patel, MD, University of California San Diego;Neal Edward Ready, MD, PhD, Duke Medical Center

July 14th 2021

Martin Dietrich, MD, PhD, shares his thoughts on PD-L1 status, tumor mutational burden, and other predictive and prognostic biomarkers when making treatment decisions for patients with stage IV non–small cell lung cancer.

Frontline Treatment Decisions for Stage IV NSCLC

Mark A. Socinski, MD, AdventHealth Cancer Institute;Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute;Roy S. Herbst, MD, PhD, Yale Cancer Center;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Sandip P. Patel, MD, University of California San Diego;Neal Edward Ready, MD, PhD, Duke Medical Center

July 7th 2021

Considerations for selecting frontline therapy for metastatic non–small cell lung cancer based on various new data and treatment approvals in the field of immunotherapy.

Frontline Treatment of Stage IV NSCLC: IPI/NIVO

Mark A. Socinski, MD, AdventHealth Cancer Institute;Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute;Roy S. Herbst, MD, PhD, Yale Cancer Center;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Sandip P. Patel, MD, University of California San Diego;Neal Edward Ready, MD, PhD, Duke Medical Center

July 7th 2021

Neal Edward Ready, MD, PhD, describes which patients with stage IV non–small cell lung cancer may benefit from the combination of ipilimumab and nivolumab in the frontline treatment setting.

Frontline I-O Monotherapy Versus Combination Therapy for PD-L1+ Stage IV NSCLC

Mark A. Socinski, MD, AdventHealth Cancer Institute;Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute;Roy S. Herbst, MD, PhD, Yale Cancer Center;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Sandip P. Patel, MD, University of California San Diego;Neal Edward Ready, MD, PhD, Duke Medical Center

June 30th 2021

Drs Roy S. Herbst and Sandip P. Patel comment on patient candidacy for immunotherapy as monotherapy to treat PD-L1+ metastatic non–small cell lung cancer versus chemoimmunotherapy.

Frontline Treatment of PD-L1+ Stage IV NSCLC: Cemiplimab

Mark A. Socinski, MD, AdventHealth Cancer Institute;Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute;Roy S. Herbst, MD, PhD, Yale Cancer Center;Chaitali Nangia, MD, Patty and George Hoag Cancer Center;Sandip P. Patel, MD, University of California San Diego;Neal Edward Ready, MD, PhD, Duke Medical Center

June 30th 2021

Roy S. Herbst, MD, PhD, of Yale Cancer Center, highlights treatment advances in stage IV non–small cell lung cancer, including cemiplimab as frontline monotherapy based on EMPOWER-Lung 1.

Rapid Readouts: Postoperative Chemotherapy Use and Outcomes from ADAURA

Roy S. Herbst, MD, PhD, Yale Cancer Center

February 19th 2021

Roy S. Herbst, MD, PhD, presents slides from the IASLC 2020 World Conference on Lung Cancer for postoperative chemotherapy use and outcomes from the phase 3 ADAURA trial of osimertinib as adjuvant therapy in patients with resected EGFR mutated NSCLC.

Rapid Readouts: Patient-Reported Outcomes from ADAURA

Roy S. Herbst, MD, PhD, Yale Cancer Center

February 19th 2021

Roy S. Herbst, MD, PhD, presents slides from the IASLC 2020 World Conference on Lung Cancer for patient-reported outcomes from the phase 3 ADAURA trial of osimertinib as adjuvant therapy in patients with resected EGFR mutated NSCLC.